GSK Boostrix May Launch By June; FDA Wants Quick sBLA With Infanrix Cohort

FDA is asking GlaxoSmithKline to submit a supplementary BLA for Boostrix with data on use of the tetanus, diphtheria and pertussis booster vaccine in patients who received a full course of the primary vaccine as part of its May 3 approval